SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001610618-24-000007
Filing Date
2024-03-04
Accepted
2024-03-04 16:22:11
Documents
4
Period of Report
2024-04-04

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT cdtxdef14a03-04x2024.htm DEF 14A 415192
2 GRAPHIC cdtx_pcx2024smxpg1.jpg GRAPHIC 2210868
3 GRAPHIC cdtx_pcx2024smxpg2.jpg GRAPHIC 2422625
4 GRAPHIC cdtxlogoa13.jpg GRAPHIC 46741
  Complete submission text file 0001610618-24-000007.txt   6840541
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36912 | Film No.: 24715233
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)